Novartis AG has announced the first published mature overall survival and updated overall response rate data following treatment with Tabrecta® in adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14).
[Novartis AG]
6445212
nan
items
1
apa
0
default
asc
1
163155
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
